Vectors Research Management LLC Has $983,000 Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Vectors Research Management LLC lowered its position in shares of Boston Scientific Co. (NYSE:BSX) by 9.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,006 shares of the medical equipment provider’s stock after selling 1,135 shares during the quarter. Vectors Research Management LLC’s holdings in Boston Scientific were worth $983,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. M&T Bank Corp lifted its position in Boston Scientific by 0.3% during the 3rd quarter. M&T Bank Corp now owns 106,127 shares of the medical equipment provider’s stock valued at $8,894,000 after purchasing an additional 370 shares during the period. Passumpsic Savings Bank bought a new position in Boston Scientific in the third quarter valued at approximately $3,015,000. World Investment Advisors LLC grew its holdings in Boston Scientific by 50.9% during the 3rd quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider’s stock worth $979,000 after acquiring an additional 3,939 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Boston Scientific during the 3rd quarter valued at $1,175,000. Finally, Tidal Investments LLC lifted its stake in shares of Boston Scientific by 8.8% in the 3rd quarter. Tidal Investments LLC now owns 86,507 shares of the medical equipment provider’s stock valued at $7,249,000 after purchasing an additional 6,990 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.2 %

Shares of BSX opened at $95.08 on Monday. The stock has a market capitalization of $140.63 billion, a PE ratio of 76.06, a P/E/G ratio of 2.79 and a beta of 0.73. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The firm’s 50 day moving average is $99.46 and its 200-day moving average is $94.48. Boston Scientific Co. has a 12 month low of $66.80 and a 12 month high of $107.17.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 6,528 shares of Boston Scientific stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the transaction, the executive vice president now owns 26,449 shares of the company’s stock, valued at $2,776,351.53. The trade was a 19.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares in the company, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 133,183 shares of company stock worth $13,948,476 in the last ninety days. Corporate insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on BSX shares. Argus set a $130.00 price objective on Boston Scientific in a report on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research note on Friday, January 10th. Needham & Company LLC raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $113.00 price objective on the stock in a research note on Wednesday, April 16th. StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 8th. Finally, Barclays boosted their price target on shares of Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a report on Monday, February 10th. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $110.22.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.